Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19.

Autor: Puranik A; nference, Cambridge, MA 02139, USA., Lenehan PJ; nference, Cambridge, MA 02139, USA., O'Horo JC; Division of Infectious Diseases, Mayo Clinic, Rochester, MN 55902, USA.; Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN 55902, USA., Pawlowski C; nference, Cambridge, MA 02139, USA., Virk A; Division of Infectious Diseases, Mayo Clinic, Rochester, MN 55902, USA., Swift MD; Division of Preventive, Occupational, and Aerospace Medicine, Mayo Clinic, Rochester, MN 55902, USA., Kremers W; Division of Biomedical Statistics, Mayo Clinic, Rochester, MN 55902, USA., Venkatakrishnan AJ; nference, Cambridge, MA 02139, USA., Challener DW; Division of Infectious Diseases, Mayo Clinic, Rochester, MN 55902, USA., Breeher L; Division of Preventive, Occupational, and Aerospace Medicine, Mayo Clinic, Rochester, MN 55902, USA., Gordon JE; Department of Family Medicine, Mayo Clinic Health System, Mankato, MN 56001, USA., Geyer HL; Division of Hospital Internal Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA., Speicher LL; Division of General Internal Medicine, Mayo Clinic, Jacksonville, FL 32224, USA., Soundararajan V; nference, Cambridge, MA 02139, USA.; nference Labs, Bengaluru, Karnataka 560017, India., Badley AD; Division of Infectious Diseases, Mayo Clinic, Rochester, MN 55902, USA.; Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55902, USA.
Jazyk: angličtina
Zdroj: PNAS nexus [PNAS Nexus] 2022 May 20; Vol. 1 (2), pp. pgac058. Date of Electronic Publication: 2022 May 20 (Print Publication: 2022).
DOI: 10.1093/pnasnexus/pgac058
Abstrakt: COVID-19 vaccines are effective, but breakthrough infections have been increasingly reported. We conducted a test-negative case-control study to assess the durability of protection against symptomatic infection after vaccination with mRNA-1273. We fit conditional logistic regression (CLR) models stratified on residential county and calendar date of SARS-CoV-2 PCR testing to assess the association between the time elapsed since vaccination and the odds of symptomatic infection, adjusted for several covariates. There were 2,364 symptomatic individuals who had a positive SARS-CoV-2 PCR test after full vaccination with mRNA-1273 ("cases") and 12,949 symptomatic individuals who contributed 15,087 negative tests after full vaccination ("controls"). The odds of symptomatic infection were significantly higher 250 days after full vaccination compared to the date of full vaccination (Odds Ratio [OR]: 2.47, 95% confidence interval [CI]: 1.19-5.13). The odds of non-COVID-19 associated hospitalization and non-COVID-19 pneumonia (negative control outcomes) remained relatively stable over the same time interval (Day 250 OR Non-COVID Hospitalization : 0.68, 95% CI: 0.47-1.0; Day 250 OR Non-COVID Pneumonia : 1.11, 95% CI: 0.24-5.2). The odds of symptomatic infection remained significantly lower almost 300 days after the first mRNA-1273 dose as compared to 4 days after the first dose, when immune protection approximates the unvaccinated state (OR: 0.26, 95% CI: 0.17-0.39). Low rates of COVID-19 associated hospitalization or death in this cohort precluded analyses of these severe outcomes. In summary, mRNA-1273 robustly protected against symptomatic SARS-CoV-2 infection at least 8 months after full vaccination, but the degree of protection waned over this time period.
(© The Author(s) 2022. Published by Oxford University Press on behalf of the National Academy of Sciences.)
Databáze: MEDLINE
Externí odkaz: